Drugs & Pharmaceuticals

Incretins (Byetta & Januvia- Diabetic drugs)

Januvia is a pioneer drug in a new class of medications designed to inhibit proteolytic activity of dipeptidyl peptidase-4 (DPP-4). Januvia was approved in October of 2006 and was released in the North American market during the same year. The drug has the effect of potentiating the action of incretins.

Both Januvia and another drug Byetta, are intended for the treatment of diabetes.  Byetta is also part of a new class of drugs, which are known as glucagib-like peptide-1 (GLP-1) receptor agonists. It was approved for sale in 2005 and marketed shortly after approval.

Adverse event reports made to the FDA suggest that both Januvia and Byetta have troubling side effects. Patients taking Byetta have a 2.9-fold greater event rate of pancreatic cancer and patients taking Januvia have a 2.7-fold increased event rate. The increased cancer risk is related to the 10-fold increase in pancreatitis among Byetta-patients and the 6-fold increase in pancreatitis of patients treated with Januvia. Pancreatitis is a major risk factor for the development of pancreatic cancer.

Neither Januvia nor Byetta carried a warning label alerting patients to the increased risk of cancer.

This is Attorney Advertising
Theclassactionnews.com is operated by the Law Offices of Jennifer Duffy, A Professional Law Corporation.
Main Office: 4601 Wilshire Blvd, Los Angeles, CA 90010
 
We invite you to contact us and welcome your calls, letters and electronic mail. Contacting us does not create an attorney-client relationship. Please do not send any confidential information to us until such time as an attorney-client relationship has been established.
 
The hiring of a lawyer is an important decision that should not be based solely upon advertisements. No representation is made that the quality of the legal services to be performed is greater than the quality of legal services performed by other lawyers. Prior results do not guarantee a similar outcome. Submission of our contact form is an agreement to receive communication from entities related to Theclassactionnews.com. While the firm maintains joint responsibility, some cases are referred to other attorneys for principle responsibility.
Show More